Recent research identifies hidden systemic inflammation in primary ciliary dyskinesia via oral swab and confirms asthma biologics do not increase respiratory infection risk in pediatric patients.
Kyowa Kirin and Kura Oncology started a Japanese Phase II registrational study of ziftomenib in adults with relapsed or refractory NPM1-mutated AML. Kyowa Kirin plans to seek regulatory approval in Japan after the trial.
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07709754 |
PULmonary Stimulation for Asthma Relief |
NOT_YET_RECRUITING | NA |
| NCT05851443 |
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma |
ACTIVE_NOT_RECRUITING | PHASE2 |
